A synthetic cytotoxic T cell platform for rapidly prototyping TCR function
Current tools for functionally profiling T cell receptors with respect to cytotoxic potency and cross-reactivity are hampered by difficulties in establishing model systems to test these proteins in the contexts of different HLA alleles and against broad arrays of potential antigens. We have implemented a granzyme-activatable sensor of T cell cytotoxicity in a universal prototyping platform which enables facile recombinant expression of any combination of TCR-, peptide-, and class I MHC-coding sequences and direct assessment of resultant responses. This system consists of an engineered cell platform based on the immortalized natural killer cell line, YT-Indy, and the MHC-null antigen-presenting cell line, K562. These cells were engineered to furnish the YT-Indy/K562 pair with appropriate protein domains required for recombinant TCR expression and function in a non-T cell chassis, integrate a fluorescence-based target-centric early detection reporter of cytotoxic function, and deploy a set of protective genetic interventions designed to preserve antigen-presenting cells for subsequent capture and downstream characterization. Our data show successful reconstitution of the surface TCR complex in the YT-Indy cell line at biologically relevant levels. We also demonstrate successful induction and highly sensitive detection of antigen-specific response in multiple distinct model TCRs. Additionally, we monitored destruction of targets in co-culture and found that our survival-optimized system allowed for complete preservation after 24 h exposure to cytotoxic effectors. With this bioplatform, we anticipate investigators will be empowered to rapidly express and characterize T cell receptor responses, generate knowledge regarding the patterns of T cell receptor recognition, and optimize therapeutic T cell receptors.
Authors
- Zahra Ali (ORCID: https://orcid.org/0000-0002-1712-8794)
- Eric Yung (ORCID: https://orcid.org/0000-0002-7328-7204)
- James Round (ORCID: https://orcid.org/0000-0003-4736-5755)
- Govinda Sharma (ORCID: https://orcid.org/0000-0002-5675-2637)
- Robert A. Holt (ORCID: https://orcid.org/0000-0002-7259-1247)
- Fei Teng (ORCID: https://orcid.org/0000-0002-6847-9885)
- Chris May
Institutions
- University of British Columbia (CA)
- Simon Fraser University (CA)
- Canada's Michael Smith Genome Sciences Centre (CA)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1038/s41698-024-00669-9
- Citations
- 4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Michael Smith Health Research BC
- Genome British Columbia
- National Institutes of Health
- National Cancer Institute